EN DE
Watch Harvard Apparatus Regenerative Technology Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Harvard Apparatus Regenerative Technology Inc (HRGN) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Harvard Apparatus Regenerative Technology Inc stock $1.14, price $2.09, that is 45.5% below the price, quality 37 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Defensive US

HA Harvard Apparatus Regenerative Technology Inc logo Thin data Nov 10, 2026

Harvard Apparatus Regenerative Technology Inc

HRGN · US
Very expensive, weak quality

Our calculation puts a fair price 45% below what the stock costs today.

Revenue last quarter +31% vs. a year ago.
Mixed Growth (revenue YoY +63.7 %/yr in USD)
Insiders bought $394,459 (6M)
Fair value $1.14 · Strongly overvalued
Quality 37/100
Negative free cash flow
Trails peers (1/5)
Narrow moat 23/100 · thin data
Thin data
Estimate
Watch Harvard Apparatus Regenerative Technology Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$7.25 $1.00 Fair Value $1.14 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $1.00 – $7.25 · fair‑value band $0.8500 – $1.42 · the $2.09 price screens above the $1.14 fair value. As of Nov 10, 2026.

Follow Harvard Apparatus Regenerative Technology in your weekly email

Every Wednesday you see whether Harvard Apparatus Regenerative Technology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects.

Show moreShow less

The company's lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease.

It's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair.

The company also sells consumer health products that focuses on personal healthcare, including dietary supplements. Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023.

The company was founded in 2009 and is headquartered in Holliston, Massachusetts.

Stock analysis

Harvard Apparatus Regenerative Technology Inc (HRGN) currently trades at $2.09, while our estimate is $1.14, 45% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.8500 (bear) to $1.42 (bull), the price of $2.09 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Consumer Defensive sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Harvard Apparatus Regenerative Technology Inc reported revenue of $704K in FY2025 versus $0 in FY2021. Reported net income was −$6.9M in FY2025.

Key figures

Market cap $36.7M Micro · P/S ratio 39.5 · EPS (TTM) $−0.3200 · Return on equity −637% · Return on assets (EBIT) −297% (5-year average) · Operating margin −409% · Revenue (TTM) $982K · Revenue growth (YoY) +30.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).

What moves the price

The share trades about 11% below its 52-week high and 109% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at 2% fair-value upside, at −45%, HRGN screens richer than that median.

Fair Value

Bear $0.8500 Fair Value $1.14 Bull $1.42
Price $2.09 · Downside -45.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 26
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 90
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 76
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 60
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $394,459, on Sep 15, 2026.

  • BuyJunli HeCEO, Director2× since Nov 25, 2025: 371,630 shares, avg. $1.08$399,559Sep 15, 2026

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

HRGN screens overvalued: fair value 45% below the price. Compare with Nestlé S.A →

Compare Harvard Apparatus Regenerative Technology Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 660 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −45.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 30.6% · Top 25%

Valuation Multiplesvs Packaged Foods median · lower = cheaper

P/B 34.76× · Priciest 25%
P/S (12 months) 37.42× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 34
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 30
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 55

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Wilmar International Limited F34 2.95 SGD 4.93 SGD +67% vs HRGN
Inner Mongolia Yili Industrial Group 600887 ¥31.14 ¥41.84 +34% vs HRGN
The Kraft Heinz Company KHC $24.24 $29.20 +20% vs HRGN
Foshan Haitian Flavouring and Food Company 603288 ¥35.46 ¥39.22 +11% vs HRGN
General Mills, Inc GIS $34.60 $35.30 +2% vs HRGN
Danone S.A BN €68.32 €50.65 −26% vs HRGN
Nestlé S.A NESN CHF 86.41 CHF 59.51 −31% vs HRGN
Kerry Group KRZ €97.10 €60.33 −38% vs HRGN
Nestlé India Limited NESTLEIND ₹1,298 ₹724.74 −44% vs HRGN
Yihai Kerry Arawana Holdings 300999 ¥25.92 ¥12.21 −53% vs HRGN

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Harvard Apparatus Regenerative Technology Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Harvard Apparatus Regenerative Technology Inc Fair Value". https://www.fairvalue-calculator.com/stock/HRGN

Frequently asked questions

Is Harvard Apparatus Regenerative Technology Inc (HRGN) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $1.14 versus a price of $2.09, about 45% lower (overvalued).
What is the fair value of HRGN?
Our estimate for Harvard Apparatus Regenerative Technology Inc is $1.14 (as of Nov 10, 2026), built from audited fundamentals. The current price: $2.09.
What is the quality score of HRGN?
Harvard Apparatus Regenerative Technology Inc has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Harvard Apparatus Regenerative Technology Inc (HRGN)?
Our calculated price target is the estimate of $1.14 (as of Nov 10, 2026). Cautious scenario $0.8500, optimistic scenario $1.42. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Harvard Apparatus Regenerative Technology Inc stock forecast for 2026?
Our estimate puts fair value at $1.14, about 45% lower versus a price of $2.09 (overvalued). Cautious scenario $0.8500, optimistic scenario $1.42. The calculation is refreshed regularly with new filings.
What is the revenue of Harvard Apparatus Regenerative Technology Inc (HRGN)?
Harvard Apparatus Regenerative Technology Inc reported trailing-twelve-month revenue of about $982K (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Harvard Apparatus Regenerative Technology Inc (HRGN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Harvard Apparatus Regenerative Technology Inc it is $1.14 per share (as of Nov 10, 2026), against a price of $2.09.
Is Harvard Apparatus Regenerative Technology Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, HRGN trades above its calculated fair value: price $2.09, fair value $1.14, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HRGN?
No. The price is what the market pays today ($2.09); the fair value is what the company's own numbers justify ($1.14). For Harvard Apparatus Regenerative Technology Inc the two are $0.9500 per share apart. That gap is exactly why we show both numbers side by side.
How much is Harvard Apparatus Regenerative Technology Inc worth?
The market values Harvard Apparatus Regenerative Technology Inc at about $36.7M (market capitalisation, as of Nov 10, 2026). Per share that is $2.09; our models calculate a fair value of $1.14 per share.
What do the bullish and bearish scenarios say about HRGN?
Our models span a range for Harvard Apparatus Regenerative Technology Inc: cautious scenario $0.8500, base $1.14, optimistic $1.42 per share (as of Nov 10, 2026, price $2.09). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is HRGN from its 52-week high?
Harvard Apparatus Regenerative Technology Inc trades at $2.09, about 11% below its 52-week high of $2.35 and 109% above the low of $1.00 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $1.14 is for.
Which stocks are comparable to Harvard Apparatus Regenerative Technology Inc?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Harvard Apparatus Regenerative Technology Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $2.09, calculated fair value $1.14 (−45%), Quality Score 37/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Harvard Apparatus Regenerative Technology Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Harvard Apparatus Regenerative Technology Inc (HRGN)?
The closing price on Nov 10, 2026 was $2.09. Our estimate is $1.14, about 45% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Harvard Apparatus Regenerative Technology Inc right now?
The price sits above even our optimistic bull case ($1.42). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Harvard Apparatus Regenerative Technology Inc

How large is the market capitalisation of Harvard Apparatus Regenerative Technology Inc (HRGN)?
The market capitalisation of Harvard Apparatus Regenerative Technology Inc is $36.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Harvard Apparatus Regenerative Technology Inc (HRGN)?
The price-to-sales ratio of Harvard Apparatus Regenerative Technology Inc is 39.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Harvard Apparatus Regenerative Technology Inc (HRGN)?
Earnings per share at Harvard Apparatus Regenerative Technology Inc are $−0.3200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Harvard Apparatus Regenerative Technology Inc (HRGN)?
The return on equity (ROE) of Harvard Apparatus Regenerative Technology Inc is −637% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Harvard Apparatus Regenerative Technology Inc (HRGN)?
On an EBIT basis the return on assets of Harvard Apparatus Regenerative Technology Inc is −297% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Harvard Apparatus Regenerative Technology Inc (HRGN)?
The operating margin of Harvard Apparatus Regenerative Technology Inc is −409% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Harvard Apparatus Regenerative Technology Inc (HRGN)?
Revenue at Harvard Apparatus Regenerative Technology Inc is growing +30.6% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Harvard Apparatus Regenerative Technology Inc (HRGN) generate?
The free cash flow of Harvard Apparatus Regenerative Technology Inc is −$3.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Harvard Apparatus Regenerative Technology Inc in the live analysis

One click puts Harvard Apparatus Regenerative Technology Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.